Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. - Wikidata - wikimedia - TriplyDB

Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis.

Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis.

http://www.wikidata.org/entity/Q35683158

about

Pharmacological Targeting of the Hepcidin/Ferroportin Axis A Survey of Strategies to Modulate the Bone Morphogenetic Protein Signaling Pathway: Current and Future Perspectives Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic Inflammation Targeting BMP signalling in cardiovascular disease and anaemia A new class of small molecule inhibitor of BMP signaling Hepcidin antagonists for potential treatments of disorders with hepcidin excess.Atherogenesis and iron: from epidemiology to cellular level.Iron and atherosclerosis: nailing down a novel target with magnetic resonance.Cholesterol and lipoprotein metabolism: Early Career Committee contribution Iron and noncontrast magnetic resonance T2* as a marker of intraplaque iron in human atherosclerosis.Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis Iron and hepcidin as risk factors in atherosclerosis: what do the genes say?Iron Stores, Hepcidin, and Aortic Stiffness in Individuals with Hypertension.Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease Bone morphogenetic protein 6 and oxidized low-density lipoprotein synergistically recruit osteogenic differentiation in endothelial cells.Increased serum hepcidin levels in subjects with the metabolic syndrome: a population study.The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease.Resveratrol protects against diet-induced atherosclerosis by reducing low-density lipoprotein cholesterol and inhibiting inflammation in apolipoprotein E-deficient mice.Hepcidin-ferroportin axis controls toll-like receptor 4 dependent macrophage inflammatory responses in human atherosclerotic plaques Does iron inhibit calcification during atherosclerosis?Iron Together with Lipid Downregulates Protein Levels of Ceruloplasmin in Macrophages Associated with Rapid Foam Cell Formation.Testing the iron hypothesis in a mouse model of atherosclerosis.The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients.Are reactive oxygen species always detrimental to pathogens?"Pumping iron"-how macrophages handle iron at the systemic, microenvironmental, and cellular levels Molecular biology of atherosclerosis.Macrophages: central regulators of iron balance.The role of iron metabolism as a mediator of macrophage inflammation and lipid handling in atherosclerosis.Zebrafish as tools for drug discovery.BMP4 enhances foam cell formation by BMPR-2/Smad1/5/8 signaling.Serum ferritin and risk for new-onset heart failure and cardiovascular events in the community.Correlates of serum hepcidin levels and its association with cardiovascular disease in an elderly general population.Bone morphogenetic protein 9 (BMP9) and BMP10 enhance tumor necrosis factor-α-induced monocyte recruitment to the vascular endothelium mainly via activin receptor-like kinase 2.Quercetin Alleviates High-Fat Diet-Induced Oxidized Low-Density Lipoprotein Accumulation in the Liver: Implication for Autophagy Regulation.Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients.Associations of plasma hepcidin with mortality risk in patients with coronary artery disease.Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology.Relation between high serum hepcidin-25 level and subclinical atherosclerosis and cardiovascular mortality in hemodialysis patients.NaoXinTong Capsules inhibit the development of diabetic nephropathy in db/db mice.The association between Hepcidin and arterial stiffness in a community-dwelling population

P2860

Q26738350-A12DEE90-2C13-4A24-B644-1F7348DD1108 Q26739015-C8FF0795-138A-4D97-8A80-FA9FF18DB442 Q26745913-06417904-F526-46C9-85A5-E876FC9A05B4 Q26783734-3AC90E4D-87BE-4C07-AAB7-93236A7166C7 Q27678000-A88166E1-A1B4-4529-B901-213DF577D7B4 Q33563777-1F2427CC-C172-4DE7-AAC7-E15012459A26 Q33595279-522F8C2A-5FF7-4AD7-9937-A8C0660EE844 Q33911344-2EF515D4-2F20-40D4-9E48-D0DE685D6A3A Q34081210-3EA719B6-EF55-4589-8BC8-A7ECBB3F121B Q34244919-688E91DB-EFC8-42C7-A1E8-3291C5A18896 Q34430634-05FAF453-84D2-4A14-83C6-E6916D3AEEF9 Q35687304-51CBB275-DF22-4442-BACE-2F1281CE3E91 Q35921291-CB1CFEF0-788D-4C11-9086-1FF9784D8789 Q36144451-6F65BB6B-0882-4C35-9F35-79B95975F43B Q36188525-A6F45C9B-5F96-4EF3-A6B6-F95EBB3095B2 Q36353620-E8CEC213-585A-4687-8CCE-C8BF309873F1 Q36373567-9F14CF9F-3F3B-40ED-8F17-CC04F19DBBAA Q36608631-9EBA7F3A-D665-437A-AD25-F5E396231E73 Q36698180-499F9635-0F61-42D7-A6B6-589FAA0F8065 Q36798107-5279C7F0-219A-4D6F-B0B3-D028F2F31F42 Q37398553-153DAE2C-657C-4C4A-BF61-87A2D53B91BA Q37430727-F8FD8090-AFB0-4A5B-AFA5-9B55C0B613C1 Q37542851-F5C27F55-4140-41D1-94AE-2C48AF32C915 Q37584947-5C3F6465-CED5-45E8-92AE-E721637D8329 Q37716856-2CF9CD03-61CB-4FDA-9FA5-212E91EED8F8 Q38125279-9CDA77B5-1773-440F-82A7-DFD69E7A14CE Q38218243-EED7DC29-9D4E-4397-973A-A509D8CF30B0 Q38249176-7AAC550C-4432-41BE-B3C2-5B5D429FB466 Q38585048-4A771866-0C96-40F5-941C-F4320510D010 Q39009358-7F2239EE-0B83-4C1C-B40D-247F32A9F477 Q40531379-7FA9F119-DB1D-4785-BC54-CE8766440E1E Q41131971-ECE64B28-F0C6-4885-9E9C-027BCDA7EE54 Q41484602-899C1F46-9D09-404D-AC33-17F3DAD47695 Q42649456-9B815D9B-AED4-4D83-9641-FEA876F1DE55 Q43860234-4F1680BB-0683-4DD3-99CC-B15DD20B36B2 Q47377511-201105D2-6BB7-4E7E-8B72-9E3E0765DCF2 Q48623654-88592490-AE84-442E-B4D3-ABE9D6D9597A Q50019277-6AABB04D-EF79-4344-9F44-1F76E975A19A Q55398039-0440955C-2088-4472-99D5-81123D0BDC6F Q58097055-89E6AA22-28CE-4952-97B4-35C45FC7088F

P2860

Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis.

http://www.wikidata.org/entity/Q35683158

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Pharmacological suppression of ...... formation and atherosclerosis.

@ast

Pharmacological suppression of ...... formation and atherosclerosis.

@en

type

label

Pharmacological suppression of ...... formation and atherosclerosis.

@ast

Pharmacological suppression of ...... formation and atherosclerosis.

@en

prefLabel

Pharmacological suppression of ...... formation and atherosclerosis.

@ast

Pharmacological suppression of ...... formation and atherosclerosis.

@en

P1433

Q35683158-BC2FC929-C959-4DD7-B82F-2DE7615C4C32

P1476

Q35683158-30484004-655C-4059-B2F3-C855F56A355F

P2093

Q35683158-046BAC64-B38E-49FC-B589-F184E04928A4

Q35683158-22095207-D83F-4FB3-839D-DC86A8FCAF07

Q35683158-5D1591AA-E312-4A45-AD14-C1BC1FACB186

Q35683158-69ADB2DF-464B-42AA-97A8-BF324CC8E590

Q35683158-6B79732F-525B-474B-8B6B-6F5DAAD765ED

Q35683158-6F94B66A-61A5-4B47-876B-0728AFB2B2E9

Q35683158-8542E687-6DD8-40A8-B484-1E23DFA7353B

Q35683158-8801B641-6E2A-4BF3-9CCE-70FC324A5243

Q35683158-9B1E552D-8B2A-4A7A-98A8-B66A867CCCE8

Q35683158-9D968964-0C99-41B7-A46C-8D9BC203E3C2

P2860

Q35683158-046DCD4C-667F-48CD-B802-5A8DFDDE815E

Q35683158-057D2835-36D3-451D-82F3-6BF78CF4864D

Q35683158-07393A25-D285-4D81-B65F-5EF08E342BA7

Q35683158-0825CC8E-D107-4EF1-897E-0F0B1DDCA94B

Q35683158-093486C7-208E-4362-B7D7-B6AFBE0FD381

Q35683158-0FE3E02F-2958-44D3-9782-8DB4718D37E6

Q35683158-28514608-10C9-4AF7-9DD3-4A53539DA5AB

Q35683158-2FE383DC-2B40-4217-B46F-D7E8D7651BCB

Q35683158-310DC87C-8BFE-490F-8DE5-08E962B6DBF7

Q35683158-3643B3DD-0363-48F9-823E-970979AB03C7

P304

Q35683158-A8ACF299-C60B-4306-852A-C8B03D915B15

P31

Q35683158-7B3BFE40-C553-4186-B7F6-DD1EE773DA81

P356

Q35683158-2D9DDC4A-FE7D-4B92-B436-39623A9D9B8B

P407

Q35683158-6F7F1448-5669-4294-BC79-0E6EAEB19AB0

P433

Q35683158-9F361D6B-B13C-473C-BEC5-A441C94BA2EA

P478

Q35683158-90789BEF-350F-4112-94FB-80B87CA24F88

P50

Q35683158-FE17A6D9-A8BE-4664-B26A-81575409A7C2

P577

Q35683158-95C2419D-2F2A-41A6-A5B4-04106337B825

P698

Q35683158-42433A40-5DFC-4A53-85D8-8A0D2C699DDC

P921

Q35683158-649D0044-BCE9-45BD-B77E-D1C205C2D7F3

P932

Q35683158-7596E53B-7A09-4E98-B5B9-5825B394EFDD

P356

ATVBAHA.111.240101

P1433

Arteriosclerosis, Thrombosis, and Vascular Biology

P1476

Pharmacological suppression of ...... formation and atherosclerosis.

@en

P2093

Aloke V Finn

http://www.w3.org/2001/XMLSchema#string

Brad Rostad

http://www.w3.org/2001/XMLSchema#string

Charles C Hong

http://www.w3.org/2001/XMLSchema#string

Daiana Weiss

http://www.w3.org/2001/XMLSchema#string

Frank Kolodgie

http://www.w3.org/2001/XMLSchema#string

Fumiyuki Otsuka

http://www.w3.org/2001/XMLSchema#string

John Elliott

http://www.w3.org/2001/XMLSchema#string

Kimberly Pachura

http://www.w3.org/2001/XMLSchema#string

Lila Adams

http://www.w3.org/2001/XMLSchema#string

Omar Saeed

http://www.w3.org/2001/XMLSchema#string

P2860

Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization

Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages

BMP type I receptor inhibition reduces heterotopic [corrected] ossification

Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis

Atherosclerosis — An Inflammatory Disease

Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo

Inflammation, atherosclerosis, and coronary artery disease

Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism

Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice.

Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification.

P304

299-307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/ATVBAHA.111.240101

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22095982

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

3262074

http://www.w3.org/2001/XMLSchema#string